These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 29804542

  • 1. DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.
    Gunardi H, Rusmil K, Fadlyana E, Soedjatmiko, Dhamayanti M, Sekartini R, Tarigan R, Satari HI, Medise BE, Sari RM, Bachtiar NS, Kartasasmita CB, Hadinegoro SRS.
    BMC Pediatr; 2018 May 28; 18(1):177. PubMed ID: 29804542
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.
    Faingezicht I, Avila-Aguerro ML, Cervantes Y, Fourneau M, Clemens SA.
    Rev Panam Salud Publica; 2002 Oct 28; 12(4):247-57. PubMed ID: 12431356
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
    Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, Verma V.
    Hum Vaccin; 2011 Apr 28; 7(4):451-7. PubMed ID: 21403463
    [Abstract] [Full Text] [Related]

  • 5. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L.
    Vaccine; 2007 Jan 22; 25(6):1055-63. PubMed ID: 17049692
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 7. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.
    Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, Lattanzi M.
    Hum Vaccin Immunother; 2013 Sep 03; 9(9):1903-9. PubMed ID: 23783081
    [Abstract] [Full Text] [Related]

  • 8. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.
    Tregnaghi M, López P, Rocha C, Rivera L, David MP, Rüttimann R, Schuerman L.
    Rev Panam Salud Publica; 2006 Mar 03; 19(3):179-88. PubMed ID: 16640847
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG.
    Vaccine; 2008 Jun 13; 26(25):3142-52. PubMed ID: 18502545
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R, PRI02C study group.
    Vaccine; 2017 Jun 27; 35(30):3764-3772. PubMed ID: 28583305
    [Abstract] [Full Text] [Related]

  • 11. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, Lefevre I.
    Hum Vaccin; 2008 Jun 27; 4(1):60-6. PubMed ID: 18376148
    [Abstract] [Full Text] [Related]

  • 12. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
    Posuwan N, Wanlapakorn N, Vongpunsawad S, Sintusek P, Leuridan E, Van Damme P, Poovorawan Y.
    Vaccine; 2020 Feb 11; 38(7):1643-1651. PubMed ID: 31948817
    [Abstract] [Full Text] [Related]

  • 13. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
    Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M.
    Pediatr Infect Dis J; 2013 Jul 11; 32(7):777-85. PubMed ID: 23838777
    [Abstract] [Full Text] [Related]

  • 14. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L.
    Vaccine; 2004 Nov 15; 23(1):14-20. PubMed ID: 15519702
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 15; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 16. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L.
    Pediatr Infect Dis J; 2006 Aug 15; 25(8):706-12. PubMed ID: 16874170
    [Abstract] [Full Text] [Related]

  • 17. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration.
    Madhi SA, López P, Zambrano B, Jordanov E, B'Chir S, Noriega F, Feroldi E.
    Hum Vaccin Immunother; 2019 Aug 15; 15(3):658-668. PubMed ID: 30513252
    [Abstract] [Full Text] [Related]

  • 18. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E.
    Pediatr Infect Dis J; 2013 Aug 15; 32(8):889-97. PubMed ID: 23538523
    [Abstract] [Full Text] [Related]

  • 19. The effect of reconstitution of an Haemophilus influenzae type b-tentanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up.
    Hoppenbrouwers K, Roelants M, Ethevenaux C, Vandermeulen C, Knops J, Desmyter J.
    Vaccine; 1999 Jun 04; 17(20-21):2588-98. PubMed ID: 10418907
    [Abstract] [Full Text] [Related]

  • 20. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H, McIntyre P, Roberton D, Dinan L, Hardt K.
    Int J Infect Dis; 2010 Jan 04; 14(1):e41-9. PubMed ID: 19467896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.